India Glycols Shareholders Approve Scheme of Arrangement
India Glycols Limited shareholders approved a Scheme of Arrangement involving Ennature Bio Pharma Limited and IGL Spirits Limited during a meeting on March 24, 2026. The resolution, requiring a special majority, passed with 100% of polled votes in favour. The NCLT had ordered the meeting.
The approval of a Scheme of Arrangement is a significant corporate action that can impact the company's structure and future operations, warranting a medium impact.
The resolution for the Scheme of Arrangement was passed with a high majority, indicating positive shareholder sentiment towards the proposed corporate restructuring.
India Glycols Limited convened a meeting of its Equity Shareholders on Tuesday, 24th March, 2026, pursuant to orders from the Hon’ble National Company Law Tribunal (NCLT), Allahabad Bench. The meeting, held via Video Conference, was to consider and approve a Scheme of Arrangement amongst India Glycols Limited, Ennature Bio Pharma Limited, and IGL Spirits Limited, along with their respective shareholders.
The resolution proposed regarding the Scheme of Arrangement was passed with the requisite majority. The meeting was chaired by Shri L.N. Gupta, appointed by the Tribunal as Chairperson. A total of 49 members attended the meeting. The e-voting facility was available from Friday, 20th March, 2026, to Monday, 23rd March, 2026, and also during the meeting. The voting results, as consolidated by the scrutinizer, indicated strong approval for the resolution. The details of the proceedings and voting results have been submitted to BSE Limited and the National Stock Exchange of India Limited, and are also hosted on the company's website and NSDL's e-voting portal.
The Scheme of Arrangement involves India Glycols Limited as the Demerged Company, Ennature Bio Pharma Limited as Resulting Company 1, and IGL Spirits Limited as Resulting Company 2. The resolution was passed as a Special Resolution, with 100% of the votes polled in favour, reflecting overwhelming support from the shareholders for this corporate restructuring.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.